Private Advisor Group LLC bought a new position in HealthEquity, Inc. (NASDAQ:HQY – Free Report) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 2,544 shares of the company’s stock, valued at approximately $208,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. International Assets Investment Management LLC purchased a new stake in HealthEquity in the 2nd quarter worth approximately $35,000. Paladin Wealth LLC bought a new position in shares of HealthEquity in the 3rd quarter worth $39,000. GAMMA Investing LLC increased its holdings in shares of HealthEquity by 114.8% in the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after buying an additional 318 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of HealthEquity in the 2nd quarter worth $73,000. Finally, Headlands Technologies LLC bought a new position in shares of HealthEquity in the 1st quarter worth $130,000. 99.55% of the stock is currently owned by hedge funds and other institutional investors.
HealthEquity Stock Up 1.7 %
NASDAQ:HQY opened at $98.82 on Friday. The firm has a market cap of $8.63 billion, a P/E ratio of 82.35, a P/E/G ratio of 1.36 and a beta of 0.52. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.10 and a current ratio of 4.10. HealthEquity, Inc. has a fifty-two week low of $62.10 and a fifty-two week high of $99.57. The firm has a 50-day simple moving average of $83.15 and a two-hundred day simple moving average of $80.43.
Analysts Set New Price Targets
HQY has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. Barrington Research reaffirmed an “outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Friday, September 20th. Bank of America reduced their target price on shares of HealthEquity from $105.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, September 4th. JMP Securities reaffirmed a “market outperform” rating and set a $105.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $103.83.
Read Our Latest Report on HealthEquity
Insider Buying and Selling at HealthEquity
In other news, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Frank Corvino sold 1,039 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the sale, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert W. Selander sold 8,250 shares of the business’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now owns 54,719 shares of the company’s stock, valued at $4,540,582.62. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,536 shares of company stock worth $884,517. 2.20% of the stock is owned by corporate insiders.
About HealthEquity
HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.
Featured Articles
- Five stocks we like better than HealthEquity
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- How to Invest in the Best Canadian Stocks
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Energy and Oil Stocks Explained
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Want to see what other hedge funds are holding HQY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HealthEquity, Inc. (NASDAQ:HQY – Free Report).
Receive News & Ratings for HealthEquity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity and related companies with MarketBeat.com's FREE daily email newsletter.